Probiotic treatment for Clostridium Difficile infection
InventionThe technology is the administration of probiotic bacterial strains with increased expression of a Clostridium difficile attachment protein. These strains, when administered in animal models challenged with high doses of a virulent C. difficile strain prevented death. BackgroundClostridium difficile is the leading cause of healthcare-associated diarrheas worldwide. Clostridium difficile has been associated with increased mortality and relapsing diseases in the past fifteen years. There is currently no treatment for C. difficile outside of antibiotics. Consumers are becoming more educated and health conscious. The US probiotics market was estimated to be $97.5 million in 2000 and the annual growth rate is estimated to be 7 percent. Consumers are purchasing more dietary supplements to prevent diseases. These are all major factors for growth in the probiotics market. ApplicationsThe technology can be commercialized as therapy for Clostridium difficile and be a new marketed medication for C difficile treatment. The technology could potentially be offered in current probiotic supplements for prevention of C difficile. AdvantagesRecombinant probiotic strains were shown to be safe in animal studies.Current available products in the pipeline entail the use of antibodies to treat C difficile infection. Probiotics may be considered a better alternative since it will replenish healthy bacteria in the gut and prevent C difficile infection.Consumers are becoming more health conscious and purchasing more supplements to prevent diseases. Probiotics may be considered a natural approach to taking medication. InventorsGayatri VedantamVK ViswanathanMichael MallozziContactTod McCauleyLicensing Manager, Tech Launch Arizona TodM@tla.arizona.eduO: 520- 626-7916
美國
